{"nctId":"NCT03952130","briefTitle":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes","startDateStruct":{"date":"2019-05-29","type":"ACTUAL"},"conditions":["Type 1 Diabetes Mellitus"],"count":354,"armGroups":[{"label":"LY900014","type":"EXPERIMENTAL","interventionNames":["Drug: LY900014","Drug: Insulin Glargine","Drug: Insulin Degludec"]},{"label":"Insulin Lispro (Humalog)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Lispro","Drug: Insulin Glargine","Drug: Insulin Degludec"]}],"interventions":[{"name":"LY900014","otherNames":["Ultra-Rapid Lispro"]},{"name":"Insulin Lispro","otherNames":["LY275585","Humalog"]},{"name":"Insulin Glargine","otherNames":[]},{"name":"Insulin Degludec","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year.\n* Participants must have HbA1c of ≥7.0 and ≤10.0%.\n* Participants must have been treated for at least 90 days prior to screening with either multiple daily injection(s) (MDI) or premixed analog/human insulin regimens at least twice daily.\n* Participants must have body mass index (BMI) of ≤35.0 kilograms per square meter (kg/m2).\n\nExclusion Criteria:\n\n* Participants must not have used other anti-hyperglycemic medications or therapies (inhaled, oral or injectable) except for metformin within 90-days prior to screening.\n* Participants must not have had more than 1 severe hypoglycemic episode within 6 months prior to screening.\n* Participants must not have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months prior to screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c)","description":"HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Pooled Country + Number of Bolus at Study Entry Stratum + Type of Basal at Lead-in Stratum + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.063"},{"groupId":"OG001","value":"-0.21","spread":"0.064"}]}]}]},{"type":"SECONDARY","title":"1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT)","description":"A standardized MMTT was used to characterize postprandial glucose control following administration of the study insulin. Serum glucose measured at 1-hour timepoint after the start of meal minus fasting serum glucose. LS mean was determined by analysis of covariance (ANCOVA) model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment (Type III sum of squares) as variables.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.8","spread":"4.23"},{"groupId":"OG001","value":"85.0","spread":"4.14"}]}]}]},{"type":"SECONDARY","title":"2-hour PPG Excursion During MMTT","description":"A standardized MMTT was used to characterize postprandial glucose control following administration of the study insulin. Serum glucose measured at 2-hour timepoint after the start of meal minus fasting serum glucose. LS mean was determined by analysis of covariance (ANCOVA) model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment (Type III sum of squares) as variables.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142.2","spread":"5.63"},{"groupId":"OG001","value":"116.7","spread":"5.49"}]}]}]},{"type":"SECONDARY","title":"Rate of Severe Hypoglycemia","description":"Severe hypoglycemia is defined as an event requiring assistance of another person to administer carbohydrate, glucagon, or other resuscitative actions. Rate of severe hypoglycemia events per 100 years during a defined period was calculated by total number of severe hypoglycemia episodes within the period divided by the cumulative days on treatment from all participants within that treatment group \\*36525 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.88","spread":null},{"groupId":"OG001","value":"5.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Documented Symptomatic Post Meal Hypoglycemia","description":"Documented symptomatic post meal hypoglycemia is an event during which typical symptoms of hypoglycemia are accompanied by blood glucose (BG) of ≤70 mg/dL \\[3.9 millimole per liter (mmol/L)\\]. The rate of documented symptomatic post meal hypoglycemia per year during a defined period is calculated by the total number of documented symptomatic post meal hypoglycemia events within the period divided by the cumulative days on treatment from all participants within that treatment group \\*365.25.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null},{"groupId":"OG001","value":"1.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.80","spread":null},{"groupId":"OG001","value":"4.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.05","spread":null},{"groupId":"OG001","value":"3.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.40","spread":null},{"groupId":"OG001","value":"7.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"10.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 1,5-Anhydroglucitol (1,5-AG)","description":"1,5-anhydroglucitol (1,5-AG) is a marker of short-term glycemic control especially postprandial hyperglycemia. It accurately predicts rapid changes in glycemia and is tightly associated with glucose fluctuations and postprandial glucose. LS mean was determined by MMRM model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.202"},{"groupId":"OG001","value":"0.10","spread":"0.203"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values","description":"SMBG 10-point profiles were measured at morning (premeal-fasting, 1-hour post meal, 2-hour post meal), midday (premeal, 1-hour post meal, 2-hour post meal), evening (premeal, 1-hour post meal, 2-hour post meal) and bedtime. LS Mean was determined by MMRM model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"2.90"},{"groupId":"OG001","value":"-10.2","spread":"2.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"3.53"},{"groupId":"OG001","value":"-20.4","spread":"3.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.5","spread":"3.63"},{"groupId":"OG001","value":"-24.4","spread":"3.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"3.25"},{"groupId":"OG001","value":"-9.0","spread":"3.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"3.34"},{"groupId":"OG001","value":"-13.8","spread":"3.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.8","spread":"3.31"},{"groupId":"OG001","value":"-14.1","spread":"3.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.2","spread":"4.00"},{"groupId":"OG001","value":"-1.6","spread":"4.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"3.54"},{"groupId":"OG001","value":"-8.0","spread":"3.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"3.50"},{"groupId":"OG001","value":"-14.8","spread":"3.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.9","spread":"3.84"},{"groupId":"OG001","value":"-12.4","spread":"3.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Daily Insulin Dose","description":"LS mean was determined by MMRM model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.24"},{"groupId":"OG001","value":"0.0","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"0.69"},{"groupId":"OG001","value":"6.6","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"0.75"},{"groupId":"OG001","value":"6.6","spread":"0.76"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7% and ≤6.5%","description":"HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.48","spread":null},{"groupId":"OG001","value":"26.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.15","spread":null},{"groupId":"OG001","value":"9.94","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":178},"commonTop":["Upper respiratory tract infection","Weight increased"]}}}